517 related articles for article (PubMed ID: 1700746)
41. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
42. Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.
Vollenweider I; Moser R; Groscurth P
Cancer Immunol Immunother; 1994 Nov; 39(5):305-12. PubMed ID: 7987862
[TBL] [Abstract][Full Text] [Related]
43. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells.
Sedlmayr P; Rabinowich H; Elder EM; Ernstoff MS; Kirkwood JM; Herberman RB; Whiteside TL
J Immunother (1991); 1991 Oct; 10(5):336-46. PubMed ID: 1790141
[TBL] [Abstract][Full Text] [Related]
44. Immunomagnetic isolation of NK and LAK cells.
Naume B; Nonstad U; Steinkjer B; Funderud S; Smeland E; Espevik T
J Immunol Methods; 1991 Jan; 136(1):1-9. PubMed ID: 1704900
[TBL] [Abstract][Full Text] [Related]
45. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
46. Human liver-associated lymphocytes: an overview.
Winnock M; Garcia Barcina M; Lukomska B; Huet S; Saric J; Balabaud C; Bioulac-Sage P
J Gastroenterol Hepatol; 1995; 10 Suppl 1():S43-6. PubMed ID: 8589341
[TBL] [Abstract][Full Text] [Related]
47. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
Miller JS; Verfaillie C; McGlave P
Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
[TBL] [Abstract][Full Text] [Related]
48. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.
Iho S; Shau HY; Golub SH
Cell Immunol; 1991 Jun; 135(1):66-77. PubMed ID: 2018984
[TBL] [Abstract][Full Text] [Related]
49. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
Parrado A; Casares S; Rodríguez-Fernández JM
Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
[TBL] [Abstract][Full Text] [Related]
50. [The precursors and effectors of human lymphokine-activated killer (LAK) cells].
Guo X
Zhonghua Yi Xue Za Zhi; 1993 May; 73(5):266-9, 317-8. PubMed ID: 8221242
[TBL] [Abstract][Full Text] [Related]
51. Binding of leukaemic blasts to various subpopulations of lymphokine-activated killer cells.
Palucka AK; Porwit A; Reizenstein P
Scand J Immunol; 1993 Feb; 37(2):179-85. PubMed ID: 7679523
[TBL] [Abstract][Full Text] [Related]
52. Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation.
Uberti J; Martilotti F; Chou TH; Kaplan J
Blood; 1992 Jan; 79(1):261-8. PubMed ID: 1370206
[TBL] [Abstract][Full Text] [Related]
53. Modulation of lymphokine release and cytolytic activities by activating peripheral blood lymphocytes via CD2.
Valentin H; Groux H; Gelin C; Chretien I; Bernard A
J Immunol; 1990 Feb; 144(3):875-82. PubMed ID: 1967277
[TBL] [Abstract][Full Text] [Related]
54. Studies on the relationship of human natural killer and lymphokine-activated killer cells with lysosomal staining and analysis of surface marker phenotypes.
Shau H; Gray D; Mitchell MS
Cell Immunol; 1988 Aug; 115(1):13-23. PubMed ID: 2456860
[TBL] [Abstract][Full Text] [Related]
55. Characterization of interleukin 2-expanded human peripheral blood lymphocytes: not only NKH-1+-NK cells but also NKH-1+ and NKH-1- T cells are LAK effectors.
Saito H; Oshimi K; Oshimi Y; Mizoguchi H
Cell Immunol; 1988 Dec; 117(2):253-63. PubMed ID: 3058317
[TBL] [Abstract][Full Text] [Related]
56. Lymphokine-activated killing by human intestinal lymphocytes.
Ebert EC; Roberts AI
Cell Immunol; 1993 Jan; 146(1):107-16. PubMed ID: 7678783
[TBL] [Abstract][Full Text] [Related]
57. LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytes.
Ferrarini M; Ferrero E; Fortis C; Poggi A; Zocchi MR
Br J Cancer; 1990 Nov; 62(5):754-7. PubMed ID: 1700922
[TBL] [Abstract][Full Text] [Related]
58. Enhancing effect of pokeweed mitogen on the proliferation and the cytotoxicity of lymphokine-activated killer cells.
Kimoto Y; Tanaka T; Fujiwara A; Fujita M; Taguchi T
Jpn J Cancer Res; 1992 Jun; 83(6):631-7. PubMed ID: 1379578
[TBL] [Abstract][Full Text] [Related]
59. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
60. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
Whiteside TL; Wang YL; Selker RG; Herberman RB
Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
